Skip to content
Plegridy(peginterferon beta-1a)
Plegridy (peginterferon beta-1a) is a protein pharmaceutical. Peginterferon beta-1a was first approved as Plegridy on 2014-07-18. It is used to treat multiple sclerosis in the USA. It has been approved in Europe to treat multiple sclerosis.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
immune system diseasesD007154
Trade Name
FDA
EMA
Plegridy
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Peginterferon beta-1a
Tradename
Proper name
Company
Number
Date
Products
Plegridypeginterferon beta-1aBiogenN-125499 RX2014-08-15
6 products
Labels
FDA
EMA
Brand Name
Status
Last Update
plegridyBiologic Licensing Application2021-01-31
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
multiple sclerosisEFO_0003885D009103G35
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L03: Immunostimulants
— L03A: Immunostimulants
— L03AB: Interferons
— L03AB13: Peginterferon beta-1a
HCPCS
No data
Clinical
Clinical Trials
23 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Relapsing-remitting multiple sclerosisD020529EFO_0003929——64111
Multiple sclerosisD009103EFO_0003885G352——147
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Covid-19D000086382U07.1——1——1
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—5————5
PharmacokineticsD0105991————1
Renal insufficiencyD051437HP_0000083N191————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePEGINTERFERON BETA-1A
INNpeginterferon beta-1a
Description
Peginterferon beta-1a', sold under the brand name Plegridy, is medication used to treat multiple sclerosis.
Classification
Protein
Drug classPEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID1211327-92-2
RxCUI1546168
ChEMBL IDCHEMBL2108677
ChEBI ID—
PubChem CID—
DrugBankDB09122
UNII IDI8309403R0 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Plegridy - Biogen
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 243 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
15,597 adverse events reported
View more details